Donor pretreatment with adenosine monophosphate-activated protein kinase activator protects cardiac grafts from cold ischaemia/reperfusion injury.

Yang C, Xu H, Cai L, Du X, Jiang Y, Zhang Y, Zhou H, Chen ZK

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery24 Nov 2015Cited by 10 (Europe PMC)

PMID26609046DOI10.1093/ejcts/ezv413PepBankPUB-26609046

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueEfficacy outcome
In rat donor hearts, AICAR pretreatment increased post-preservation myocardial ATP versus vehicle.
In plain wordsIn lab tests on rat hearts, AICAR pretreatment increased ATP after preservation compared with vehicle.
Peptide
AICAR (acadesine)
Outcome
IncreasePost-preservation myocardial ATP
Study
ratn: not reported in source
Sprague-Dawley donor heart cold ischaemia/reperfusion
Comparator
Vehicle
Outcome group
Mitochondrial function · Cardiovascular
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Measurements
ATP
3.247 µmol/g protein
AICAR
ATP
1.817 µmol/g protein
control
Source sentences
Summary
After preservation, myocardial ATP content in the pretreated hearts was significantly higher than in the control hearts (3.247 ± 0.3034 vs 1.817 ± 0.2533 µmol/g protein; P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Donor Sprague-Dawley rats were injected intravenously with AMPK activator 5-amino-imidazole-4-carboxamide ribonucleotide (AICAR) or vehicle 30 min before heart procurement.
Summary · context
Heart grafts were then preserved in histidine-tryptophan-ketoglutarate (HTK) solution at 4°C for 8 h.
Summary · context
After preservation, grafts were immediately mounted on the Langendorff perfusion system and perfused with Krebs-Henseleit buffer at 37°C for 1 h.
Report a problemFND-2660904601
02LabEx vivo tissueEfficacy outcome
In rat donor hearts, AICAR pretreatment increased coronary flow after reperfusion versus vehicle.
In plain wordsIn lab tests on rat hearts, AICAR pretreatment increased coronary flow after reperfusion compared with vehicle.
Peptide
AICAR (acadesine)
Outcome
IncreasePost-reperfusion coronary flow
Study
ratn: not reported in source
Sprague-Dawley donor heart cold ischaemia/reperfusion
Comparator
Vehicle
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Measurements
Coronary flow
9.667 ml/min
AICAR
Coronary flow
8.033 ml/min
vehicle
Source sentences
Summary
AICAR-pretreated heart grafts exhibited significantly higher coronary flow (9.667 ± 0.3159 vs 8.033 ± 0.2459 ml/min; P < 0.05) and left ventricular developing pressure (58.67 ± 2.894 vs 42.67 ± 3.333 mmHg; P < 0.05) than the vehicle treated after reperfusion.
3 context sentences(design, population, supporting numbers)
Summary · context
Donor Sprague-Dawley rats were injected intravenously with AMPK activator 5-amino-imidazole-4-carboxamide ribonucleotide (AICAR) or vehicle 30 min before heart procurement.
Summary · context
Heart grafts were then preserved in histidine-tryptophan-ketoglutarate (HTK) solution at 4°C for 8 h.
Summary · context
After preservation, grafts were immediately mounted on the Langendorff perfusion system and perfused with Krebs-Henseleit buffer at 37°C for 1 h.
Report a problemFND-2660904602
03LabEx vivo tissueEfficacy outcome
In rat donor hearts, AICAR pretreatment increased left ventricular developing pressure after reperfusion versus vehicle.
In plain wordsIn lab tests on rat hearts, AICAR pretreatment increased left ventricular developing pressure after reperfusion compared with vehicle.
Peptide
AICAR (acadesine)
Outcome
IncreaseLeft ventricular developing pressure
Study
ratn: not reported in source
Sprague-Dawley donor heart cold ischaemia/reperfusion
Comparator
Vehicle
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Measurements
Left ventricular developing pressure
58.67 mmHg
AICAR
Left ventricular developing pressure
42.67 mmHg
vehicle
Source sentences
Summary
AICAR-pretreated heart grafts exhibited significantly higher coronary flow (9.667 ± 0.3159 vs 8.033 ± 0.2459 ml/min; P < 0.05) and left ventricular developing pressure (58.67 ± 2.894 vs 42.67 ± 3.333 mmHg; P < 0.05) than the vehicle treated after reperfusion.
3 context sentences(design, population, supporting numbers)
Summary · context
Donor Sprague-Dawley rats were injected intravenously with AMPK activator 5-amino-imidazole-4-carboxamide ribonucleotide (AICAR) or vehicle 30 min before heart procurement.
Summary · context
Heart grafts were then preserved in histidine-tryptophan-ketoglutarate (HTK) solution at 4°C for 8 h.
Summary · context
After preservation, grafts were immediately mounted on the Langendorff perfusion system and perfused with Krebs-Henseleit buffer at 37°C for 1 h.
Report a problemFND-2660904603
04LabEx vivo tissueEfficacy outcome
In rat donor hearts, AICAR pretreatment reduced cumulative creatine kinase release versus vehicle.
In plain wordsIn lab tests on rat hearts, AICAR pretreatment reduced cumulative creatine kinase release compared with vehicle.
Peptide
AICAR (acadesine)
Outcome
DecreaseCreatine kinase release
Study
ratn: not reported in source
Sprague-Dawley donor heart cold ischaemia/reperfusion
Comparator
Vehicle
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Measurements
CK
300 U/l
AICAR
CK
431.7 U/l
control
Source sentences
Summary
Cumulative release of CK (300.0 ± 25.30 vs 431.7 ± 42.39 U/l; P < 0.05) and LDH (228.0 ± 16.68 vs 366.8 ± 57.41 U/l; P < 0.05) in the perfusate was significantly lower in the AICAR-pretreated group than that in the control group.
3 context sentences(design, population, supporting numbers)
Summary · context
Donor Sprague-Dawley rats were injected intravenously with AMPK activator 5-amino-imidazole-4-carboxamide ribonucleotide (AICAR) or vehicle 30 min before heart procurement.
Summary · context
Heart grafts were then preserved in histidine-tryptophan-ketoglutarate (HTK) solution at 4°C for 8 h.
Summary · context
After preservation, grafts were immediately mounted on the Langendorff perfusion system and perfused with Krebs-Henseleit buffer at 37°C for 1 h.
Report a problemFND-2660904604
05LabEx vivo tissueEfficacy outcome
In rat donor hearts, AICAR pretreatment reduced cumulative lactate dehydrogenase release versus vehicle.
In plain wordsIn lab tests on rat hearts, AICAR pretreatment reduced cumulative lactate dehydrogenase release compared with vehicle.
Peptide
AICAR (acadesine)
Outcome
DecreaseLactate dehydrogenase release
Study
ratn: not reported in source
Sprague-Dawley donor heart cold ischaemia/reperfusion
Comparator
Vehicle
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Measurements
LDH
228 U/l
AICAR
LDH
366.8 U/l
control
Source sentences
Summary
Cumulative release of CK (300.0 ± 25.30 vs 431.7 ± 42.39 U/l; P < 0.05) and LDH (228.0 ± 16.68 vs 366.8 ± 57.41 U/l; P < 0.05) in the perfusate was significantly lower in the AICAR-pretreated group than that in the control group.
3 context sentences(design, population, supporting numbers)
Summary · context
Donor Sprague-Dawley rats were injected intravenously with AMPK activator 5-amino-imidazole-4-carboxamide ribonucleotide (AICAR) or vehicle 30 min before heart procurement.
Summary · context
Heart grafts were then preserved in histidine-tryptophan-ketoglutarate (HTK) solution at 4°C for 8 h.
Summary · context
After preservation, grafts were immediately mounted on the Langendorff perfusion system and perfused with Krebs-Henseleit buffer at 37°C for 1 h.
Report a problemFND-2660904605
06LabEx vivo tissueMechanism
In rat donor hearts, AICAR pretreatment reduced myocardial MDA content versus vehicle.
In plain wordsIn lab tests on rat hearts, AICAR pretreatment reduced MDA content compared with vehicle.
Peptide
AICAR (acadesine)
Outcome
DecreaseMyocardial MDA content
Study
ratn: not reported in source
Sprague-Dawley donor heart cold ischaemia/reperfusion
Comparator
Vehicle
Outcome group
Oxidative stress · Cardiovascular
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Measurements
MDA
0.5167 nmol/mg protein
AICAR
MDA
0.9333 nmol/mg protein
control
Source sentences
Summary
Myocardial MDA content was also reduced in the pretreated group (0.5167 ± 0.1046 vs 0.9333 ± 0.1333 nmol/mg protein; P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Donor Sprague-Dawley rats were injected intravenously with AMPK activator 5-amino-imidazole-4-carboxamide ribonucleotide (AICAR) or vehicle 30 min before heart procurement.
Summary · context
Heart grafts were then preserved in histidine-tryptophan-ketoglutarate (HTK) solution at 4°C for 8 h.
Summary · context
After preservation, grafts were immediately mounted on the Langendorff perfusion system and perfused with Krebs-Henseleit buffer at 37°C for 1 h.
Report a problemFND-2660904606
07LabEx vivo tissueMechanism
In rat donor hearts, microscopy suggested better mitochondrial structural preservation with AICAR pretreatment versus vehicle.
In plain wordsIn lab tests on rat hearts, microscopy suggested better mitochondrial structural preservation with AICAR pretreatment than with vehicle.
Peptide
AICAR (acadesine)
Outcome
IncreaseMitochondrial structural preservation
Study
ratn: not reported in source
Sprague-Dawley donor heart cold ischaemia/reperfusion
Comparator
Vehicle
Outcome group
Mitochondrial function · Cardiovascular
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Source sentences
Summary
TEM suggested that the mitochondrial structure of AICAR-pretreated hearts was much better preserved.
3 context sentences(design, population, supporting numbers)
Summary · context
Donor Sprague-Dawley rats were injected intravenously with AMPK activator 5-amino-imidazole-4-carboxamide ribonucleotide (AICAR) or vehicle 30 min before heart procurement.
Summary · context
Heart grafts were then preserved in histidine-tryptophan-ketoglutarate (HTK) solution at 4°C for 8 h.
Summary · context
After preservation, grafts were immediately mounted on the Langendorff perfusion system and perfused with Krebs-Henseleit buffer at 37°C for 1 h.
Report a problemFND-2660904607
08LabEx vivo tissueMechanism
In rat donor hearts, AICAR pretreatment reduced cytosolic cytochrome c release after reperfusion versus vehicle.
In plain wordsIn lab tests on rat hearts, AICAR pretreatment reduced cytosolic cytochrome c release after reperfusion compared with vehicle.
Peptide
AICAR (acadesine)
Outcome
DecreaseCytosolic cytochrome c release
Study
ratn: not reported in source
Sprague-Dawley donor heart cold ischaemia/reperfusion
Comparator
Vehicle
Outcome group
Mitochondrial function · Cardiovascular
Studied dose
Dose not stated · intravenousAs given in this study (rat).
Source sentences
Summary
Moreover, AICAR-pretreated hearts significantly diminished cytosolic cytochrome c release after reperfusion.
3 context sentences(design, population, supporting numbers)
Summary · context
Donor Sprague-Dawley rats were injected intravenously with AMPK activator 5-amino-imidazole-4-carboxamide ribonucleotide (AICAR) or vehicle 30 min before heart procurement.
Summary · context
Heart grafts were then preserved in histidine-tryptophan-ketoglutarate (HTK) solution at 4°C for 8 h.
Summary · context
After preservation, grafts were immediately mounted on the Langendorff perfusion system and perfused with Krebs-Henseleit buffer at 37°C for 1 h.
Report a problemFND-2660904608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.